KIF20A (kinesin family member 20A) is a mitotic kinesin essential for cytokinesis and cell division. As a member of the kinesin-6 subfamily, KIF20A functions in central spindle organization during anaphase and mediates chromosome 5 through its microtubule motor activity 1. Following phosphorylation by PLK1, KIF20A recruits PLK1 to the central spindle and interacts with GTP-bound RAB6A/B to facilitate retrograde Golgi membrane transport 1. The protein exhibits plus-end directed microtubule motility and is regulated by the chr5 passenger complex during late mitosis. KIF20A is significantly dysregulated in multiple cancers. Meta-analysis of 25 studies involving 7,262 patients demonstrated that high KIF20A expression correlates with shorter overall survival (HR=1.77), advanced clinical stage, lymph node metastasis, and distant metastasis 2. Mechanistically, KIF20A promotes cancer progression through multiple pathways: it is a key FOXM1 downstream effector inhibited by cucurbitacin B in conjunctival melanoma 3, marks a hypoxia-associated high-risk glioma subpopulation driving progression to glioblastoma 4, and competes with FBXW7 to inhibit c-Myc degradation in hepatocellular carcinoma 5. KIF20A inhibition synergizes with anti-PD-1 immunotherapy in HCC 5 and has been evaluated in clinical trials as a therapeutic target 6, establishing it as a promising prognostic biomarker and therapeutic target across cancer types.